SCR-A006 / Simcere - LARVOL DELTA

SCR-A006, an innovative and potential best-in-class EGFR/cMet bispecific antibody-drug conjugate (AACR 2025) - "SCR-A006 also showed good efficacy and was superior to benchmark ADC in amivantamab resistant xenograft models. Taken together, these findings highlight the potential of SCR-A006 as a therapeutic candidate for broad treatment of solid tumors and with a larger therapeutic window than other EGFR/cMET BsADCs. IND enabling studies of SCR-A006 are currently underway, and planned to initiate clinical study in 2025."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR